The current status of pyoderma gangrenosum

Pyoderma gangrenosum (PG) is a destructive inflammatory skin disease with distinctive clinical features. The diagnosis depends entirely on clinical evaluation since no specific histopathological features or laboratory abnormalities occur. Since its original description (Brunsting, Goeckerman & O'Leary, 1930) PG has been reported in association with an increasing number of systemic diseases. In recent years there have been reports of abnormalities of humoral and cell mediated immunity and disorders of polymorphonuclear neutrophil function in patients with PG. Despite diverse eiinical associations and investigative findings, the pathogenesis of the disorder remains unknown and consequently there is no rational basis for therapy. The purpose of this artiele is to review the reeent elinieal and investigative lindings related to this disease and to summarize the present-day management of the disorder.

[1]  G. Nuki,et al.  Pyoderma Gangrenosum: CLINICAL AND LABORATORY FINDINGS IN 15 PATIENTS WITH SPECIAL REFERENCE TO POLYARTHRITIS , 1980, Medicine.

[2]  C. Dahlgren,et al.  The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis. , 1978, The Journal of clinical investigation.

[3]  P. Nilsson,et al.  Pyoderma gangrenosum associated with regional enteritis. Improvement in defective granulocyte function and healing of skin lesions during administration of clofazimine. , 2009, Acta medica Scandinavica.

[4]  J. Callen,et al.  Recurrent pyoderma gangrenosum and agnogenic myeloid metaplasia. , 1977, Archives of dermatology.

[5]  R. Clayton.  Pyoderma gangrenosum with cellular immunity defect and red cell aplasia. , 1977, Proceedings of the Royal Society of Medicine.

[6]  L. Biró,et al.  Pyoderma gangrenosum with carcinoid tumor. , 1976, Cutis.

[7]  M. Zabel.  [Pyoderma gangrenosum with IgG-paraproteinemia in plasmacytoma]. , 1976, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[8]  R. Pye,et al.  Metal corrosion by chloride in sweat , 1976, The British journal of dermatology.

[9]  J. Byrne,et al.  Pyoderma gangrenosum associated with active chronic hepatitis: report of two cases. , 1976, Archives of dermatology.

[10]  D. Sachar,et al.  THE EXTRA-INTESTINAL COMPLICATIONS OF CROHN'S DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTS , 1976, Medicine.

[11]  G. Michaëlsson,et al.  Clofazimine. A new agent for the treatment of pyoderma gangrenosum. , 1976, Archives of dermatology.

[12]  R. Whitehead,et al.  T AND B LYMPHOCYTES IN BREAST CANCER STAGE RELATIONSHIP AND ABROGATION OF T-LYMPHOCYTE DEPRESSION BY ENZYME TREATMENT IN VITRO , 1976, The Lancet.

[13]  E. Goetzl,et al.  "Streaking leukocyte factor," arthritis, and pyoderma gangrenosum. , 1975, Pediatrics.

[14]  R. Newcombe,et al.  Lymphocyte response to PHA in breast cancer: correlation of predicted prognosis to response to different PHA concentrations. , 1975, Clinical oncology.

[15]  D. Rosenthal,et al.  Pyoderma Gangrenosum and rheumatoid arthritis. , 1975, Archives of dermatology.

[16]  Dantzig Pi.  Letter: Pyoderma gangrenosum. , 1975 .

[17]  J. Crouch,et al.  Hyperbaric oxygen therapy for pyoderma gangrenosum. , 1974, Archives of dermatology.

[18]  R. Couch,et al.  Effects of tetracycline on leukotaxis. , 1974, The Journal of infectious diseases.

[19]  J. S. Beck,et al.  Studies on a patient with leucocytoclastic vasculitis ‘pyoderma gangrenosum’ and paraproteinaemia , 1973, The British journal of dermatology.

[20]  G. Achten,et al.  PYODERMA GANGRENOSUM WITH ALTERED CELLULAR IMMUNITY AND DERMONECROTIC FACTOR * , 1972, The British journal of dermatology.

[21]  R. Winkelmann,et al.  Bullous pyoderma gangrenosum and leukemia. , 1972, Archives of dermatology.

[22]  F. Gardner,et al.  Granulocyte and platelet functions in paroxysmal nocturnal hemoglobinuria. , 1972, Series haematologica.

[23]  L. Goldsmith,et al.  Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis. , 1972, Archives of dermatology.

[24]  W. Buchanan,et al.  Immunological responses in Sjogren's syndrome and rheumatoid arthritis. , 1971, Clinical and experimental immunology.

[25]  A. Mowat,et al.  Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. , 1971, The Journal of clinical investigation.

[26]  C. McCall,et al.  Functional characteristics of human toxic neutrophils. , 1971, The Journal of infectious diseases.

[27]  J. Cream.  PYODERMA GANGRENOSUM WITH A MONOCLONAL IgM RED CELL AGGLOMERATING FACTOR , 1971, The British journal of dermatology.

[28]  B. Zegers,et al.  Monoclonal gammopathy (IgG) and chronic ulcerative dermatitis (phagedenic pyoderma). , 2009 .

[29]  M. L. Johnson,et al.  Skin lesions in ulcerative colitis. , 1969, Gut.

[30]  R. Goltz,et al.  Pyoderma gangrenosum, rheumatoid arthritis, and diabetes mellitus. , 1966, Archives of dermatology.

[31]  C. Corley,et al.  Azathioprine therapy of "autoimmune" diseases. , 1966, The American journal of medicine.

[32]  R. Penny,et al.  Studies on Neutrophil Function. II. PATHOLOGICAL ASPECTS , 1966, British journal of haematology.

[33]  I. Sluis.  Two Cases of Pyoderma (Ecthyma) Gangraenosum Associated with the Presence of an Abnormal Serumprotein (β2A-paraprotein) , 1966 .

[34]  S. Truelove,et al.  Course and prognosis of ulcerative colitis , 1964 .

[35]  A. Lorincz,et al.  Sulfapyridine and sulfone type drugs in dermatology. , 1962, Archives of dermatology.

[36]  V. Wright,et al.  The arthritis of ulcerative colitis. , 1959, Medicine.

[37]  S. Ayres.  Pyoderma gangrenosum with an unusual syndrome of ulcers, vesicles, and arthritis. , 1958, A.M.A. archives of dermatology.

[38]  H. Perry,et al.  Pyoderma Gangrenosum: A Clinical Study of Nineteen Cases , 1957 .

[39]  B. Russell.  PHAGEDENIC AND GANGRENOUS ULCERATION OF THE SKIN COMPLICATING ULCERATIVE COLITIS (PHAGEDENA GEOMETRICUM) , 1950 .